CITIUS PHARMACEUTICALS INC (CTXR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.59-2.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CTXR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to expand commercial sales, institutional adoption, and payer coverage of LYMPHIR to build a sustainable revenue stream.
Stated as a priority in 3 of last 3 quarters. Revenue from LYMPHIR grew from $5.6 million in 2026-Q1 to $7.1 million for the first nine months of 2026, with gross margins around 67-77%. Institutional vial orders increased by 31% and new institutions ordering grew 80% in 2026-Q3. Management is delivering commercial growth and expanding payer coverage as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“LYMPHIR launch continued to build momentum with increased institutional vial orders and expanded commercial teams.”
“83% of target accounts had added or were actively progressing LYMPHIR through formulary review; near 100% payer coverage.”
“Citius Oncology generated $5.6 million in net revenue since December 2025 launch of LYMPHIR.”
Progress investigator-initiated Phase 1 studies of LYMPHIR combined with pembrolizumab and prior to CAR-T therapy to explore broader oncology applications.
Stated as a priority in 3 of last 3 quarters. Phase 1 investigator-initiated studies showed a 24% overall response rate and 48% clinical benefit rate with pembrolizumab, and an 86% objective response rate including 57% complete response prior to CAR-T therapy. Median progression-free survival reached 20.5 months in responders. Management is delivering encouraging clinical data supporting combination therapy development.
“Phase 1 data presented at ASCO and ASTCT showed encouraging clinical activity and durable responses for LYMPHIR combinations.”
“Positive topline Phase 1 data from investigator-initiated studies with pembrolizumab and CAR-T therapy presented.”
“Phase 1 investigator-initiated study data presented at ASCO demonstrated durable responses and manageable tolerability.”
Raise capital through equity offerings, warrant exercises, and debt facilities to fund operations and expand LYMPHIR commercialization.
Stated as a priority in 3 of last 3 quarters. The company raised $5 million in a registered direct offering in 2026-Q2, secured up to $36.5 million in debt and equity financing, and received $9.7 million from warrant exercises plus $10 million loan tranche in 2026-Q3. Management is delivering financing to support operations and commercial expansion.
“Received approximately $9.7 million from warrant exercises and funded $10 million under a $25 million term loan facility.”
“Closed $5 million registered direct offering; secured up to $36.5 million in combined debt and equity financing.”
“Raised $5 million in registered direct offering; secured $10 million loan tranche and $11.5 million from warrant exercises.”
Continue regulatory interactions and development efforts for Mino-Lok catheter lock solution and Halo-Lido topical formulation.
Stated as a priority in 2 of last 3 quarters. Management continues FDA engagement for Mino-Lok and Halo-Lido following completion of Phase 3 and Phase 2b trials in 2023. No new financial metrics disclosed, indicating ongoing regulatory focus with limited new delivery data.
“We remain focused on advancing Mino-Lok and Halo-Lido with the FDA and disciplined execution.”
“Continued FDA engagement on Mino-Lok and Halo-Lido programs.”
Address Nasdaq's $1.00 per share bid price requirement to maintain listing on the Nasdaq Capital Market.
Newly stated in 2026-Q3. The company received a Nasdaq extension through February 8, 2027 to regain compliance with the $1.00 per share bid price requirement. No financial improvement in share price or related metrics disclosed yet, indicating this is an ongoing regulatory compliance priority.
“Received formal notice granting extension through February 8, 2027 to evidence compliance with Nasdaq bid price rule.”
Over the trailing year it converted 0.79x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
22 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.